Collaboration between Biohaven and Merus to co-develop three novel bispecific antibody drug conjugates

From GlobeNewswire: 2025-01-12 20:04:12

Biohaven Ltd. and Merus N.V. announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates. Biohaven will be responsible for preclinical ADC generation of three Merus bispecific antibodies, with the agreement including two Merus bispecific programs and one program under preclinical research by Merus. Merus will receive an upfront payment and license fee at ADC candidate nomination of the first program. The collaboration aims to create highly differentiated multispecific ADCs leveraging innovative conjugation and payload technologies to benefit patients across various cancer types. The parties plan to share further development and commercialization costs upon mutual agreement to advance each program.

This collaboration between Biohaven and Merus aims to advance bispecific antibody candidate ADCs based on the Merus Biclonics platform. The combination of Biclonics technology, validated by FDA approval of Bizengri and clinical success with petosemtamab, along with Biohaven’s suite of ADC technologies, has the potential to generate new and differentiated bispecific therapies. Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, while Biohaven is focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas including immunology, neuroscience, and oncology. Both companies are leveraging their expertise and technologies to create optimized ADCs with enhanced efficacy and safety profiles.



Read more at GlobeNewswire: Merus and Biohaven Announce Collaboration to Co-Develop